LENSAR Q4 2022 revenue $10.2M (-9% YoY); net loss narrows to $2.5M from $3.9M

LENSAR, Inc.

Q4 2022 total revenue $10.2M, down 9% from $11.2M in Q4 2021 due to lower South Korea procedure revenue.
Net loss Q4 2022: $2.5M ($0.24 per share) vs $3.9M ($0.41) in Q4 2021; Adjusted EBITDA improved to ($0.065M) from ($1.6M).
Installed ten ALLY Adaptive Cataract Treatment Systems in 2022; contracts signed for six more systems, installations expected H1 2023.
SG&A expenses rose 24% to $7.2M, driven by ALLY promotion; R&D fell 53% to $1.6M as ALLY development costs normalized.
CEO reports positive surgeon feedback: ALLY cuts 1-1.5 hours from surgical day, supports faster case volume.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LENSAR, Inc. reported the quarter ended December 31, 2022 results: revenue $10.2 million, net income $2.5 million, or ($0.24) per share, EPS ($0.24) per share.

Period: the quarter ended December 31, 2022
Revenue: $10.2 million
Net income: $2.5 million, or ($0.24) per share
EPS: ($0.24) per share
Result: reported results

Exact text from the filing

and so accurate that I have added at least 3 to 4 cases onto my surgery days." Fourth Quarter 2022 Financial Results Total revenue for the quarter ended December 31, 2022 was $10.2 million, a decrease of $1.0 million, or 9%, compared to total revenue of $11.2 million for the quarter ended December 31, 2021. The decrease from the fourth quarter of 2021 was primarily

View on SEC.gov

Browse all earnings releases →

LENSAR, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-008301

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.